邵一鸣 （全国政协委员、中国疾病预防控制中心艾滋病首席专家）
艾滋病疫苗研究旨在建立免疫保护的屏障，是一项面向国家重大需求的科学难题，疫苗试验周期长，花费巨大，单兵作战难有大作为，必须靠政府支持，进行多系统、多学科的联合攻关。我感到非常高兴的是，艾滋病等重大传染病防治被列为国家科技重大专项。
把重大科技专项和国家疾病防治计划结合起来，才能提高防治工作的科学性，使艾滋病防治有效且有可持续性。该专项已经形成了上下游各团队资源共享、信息交流、联合攻关的新研发机制。在专项支持下，我国自主知识产权的艾滋病疫苗计划取得阶段性进展。
由中国疾病预防控制中心和北京生研所共同研制的DNA—天坛痘苗复合型艾滋病疫苗已完成Ⅰb期临床试验，在人体观察到良好的安全性和特异性免疫应答，达到设计指标。目前已完成Ⅱ期临床试验疫苗的GMP（良好作业规范）生产，并通过国家鉴定，正准备向国家药监局正式提出Ⅱ期临床试验的申请。清华大学牵头的合作团队在灵长类动物模型采用系统与粘膜免疫相结合的病毒载体疫苗，获得了很好的保护性数据。北京工业大学团队研制的治疗性疫苗已获国家食品药品监督管理局的批准，即将开始I期临床试验。此外，我国科研团队还筛选出能在实验猴体内诱导出高强而持久的抗艾滋病病毒免疫反应的粘膜疫苗配方；探索并验证了能够活化广谱抗艾滋病病毒免疫反应的疫苗技术。
2009年，国内4个大的疫苗合作团队及3个疫苗评价平台结成了中国艾滋病疫苗联盟,主要从事艾滋病疫苗研究的几十家研发单位和企业强强联合，协作攻关，实现基础研究和临床试验的平行推进。联盟的目的是促进交流，协调合作，减少重复，实现资源共享。以前的科研往往是独立课题，现在是多PI（实验室研究组长）课题，谁在哪方面最强就应把优势力量集中整合到哪儿去，以保障整个联盟里每一个单元都是最好的。这样才能更好地完成国家任务，也可以更好地参与国际合作。
现在，这30多家单位每年召开学术年会，共同讨论选题，凝练目标，进行信息交流，加强国际合作。联盟的建立推动了亚洲艾滋病疫苗合作网络的成立，中国艾滋病疫苗联盟被推举承担亚洲艾滋病疫苗合作网络秘书处工作，协调亚洲各国科学家艾滋病疫苗的交流与合作。
艾滋病疫苗的研制是一项艰巨的系统工程，不能寄希望于短期内解决，也无法依靠少数队伍甚至少数国家解决，只有全球联合起来才能有所作为。我国是发展中国家中艾滋病疫苗研究的一支重要力量，我国疫苗研究着眼于上下游衔接，产学研结合，这与其他发展中国家形成了很好的互补。“十二五”期间，我们将继续推进不同技术路线的新型艾滋病疫苗研发，为疫苗的突破奠定基础。
(科技日报)
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
AIDS vaccine research to the voice of Chinese
Source: Science and Technology Daily at 01:19 on March 13th, 2011
Shao Yiming (CPPCC member, Center for Disease Control and Prevention of AIDS in China Chief Expert)
AIDS vaccine research is to establish the immune barrier protection is a major national needs for scientific problems, vaccine testing cycle is long, costly and difficult to combat big as a man, must rely on government support, multi-system, multi-disciplinary The joint research. I am very pleased that the major infectious diseases such as AIDS prevention and control of major projects listed as national science and technology.
The major science and technology and the combination of national disease control programs in order to improve prevention and treatment of science, so that effective and sustainable prevention and treatment of AIDS. This has formed a special team of upstream and downstream resource sharing, information exchange, joint research of the new R & D mechanism. In the special support of our own intellectual property AIDS vaccine program made progress.
By the China Disease Prevention and Control Center and Beijing Institute of Health jointly developed by vaccinia virus DNA-Temple of Heaven compound AIDS vaccine clinical trials Wancheng Ⅰ b, observed in human security and well-specific immune response, to meet the design targets. Has completed Phase Ⅱ clinical trial of vaccines GMP (Good Manufacturing Practices) production, and through the national identification, the State Food and Drug Administration is preparing a formal application for phase Ⅱ clinical trial. Tsinghua University, co-led the team in the primate model system and mucosal immunity using a combination of viral vector vaccine, access to good data protection. Beijing University of Technology team, therapeutic vaccines have been developed by the State Food and Drug Administration approval, is about to begin Phase I clinical trials. In addition, our research team also screened in vivo in monkeys induced high strength and long-lasting anti-HIV mucosal immune response vaccine formulations; to explore and verify the ability to activate broad-spectrum anti-HIV immune responses in vaccine technology.
In 2009, the domestic four major vaccine co-vaccination assessment team and three of China's AIDS vaccine platform to form alliances, mainly engaged in AIDS vaccine R & D units and dozens of corporate combination, collaborative research, basic research and clinical implementation parallel advance of trial. Alliance aims to promote communication, coordination and cooperation, reducing duplication, sharing of resources. Is often independent of the previous research topic, it is a multi-PI (Lab Research Leader) subjects, who in what should be the strongest advantages to concentrate into where to go, to protect the entire league is the best of each unit The. Countries in order to better accomplish the task, you can better participate in international cooperation.
Now, more than 30 units of this academic year the annual meeting, to discuss topics, concise objectives, information exchange, strengthening international cooperation. Alliance established to promote cooperation network in Asia AIDS vaccine establishment, the Chinese commitment to AIDS Vaccine Alliance, was elected co-operation network in Asia AIDS vaccine work of the Secretariat to coordinate AIDS vaccine scientists from various countries of Asia exchange and cooperation.
AIDS vaccine is a difficult system engineering, can not hope to solve the short term, can not rely on a few teams and even a small number of countries to address, and only together can make a difference globally. China AIDS vaccine research in developing countries as an important force, our vaccine research focuses on the upstream and downstream convergence, Combination, which is the formation of other developing countries complement each other well. "Twelfth Five-Year" period, we will continue to promote the new routes of different technologies AIDS vaccine research and development, the basis for the vaccine breakthrough.
(Science and Technology Daily)
